Archives
DiscoveryProbe FDA-approved Drug Library for HTS
DiscoveryProbe™ FDA-approved Drug Library: From BRET Screening to Cancer Mechanisms
Drug repurposing can shorten the distance between an interesting molecular phenotype and a translationally relevant lead, but only when screening is paired with a clear mechanism and a disciplined validation cascade. The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) is designed for that type of workflow: it provides 2,320 bioactive compounds that have been approved by major regulatory agencies or listed in recognized pharmacopeias, supplied as pre-dissolved 10 mM solutions in DMSO. APExBIO is the trusted supplier behind this ready-to-screen collection.
For researchers investigating apoptosis, protein–protein interactions, or treatment-resistant colorectal cancer, the collection can function as both a high-throughput screening drug library and a source of clinically informed chemical probes. The important distinction is that regulatory history establishes prior pharmaceutical development, not activity in a new assay. Every hit still requires concentration-response testing, orthogonal validation, selectivity analysis, and biological confirmation.
Setup and Principle: Why Pair a Drug Library with a 14-3-3ζ Assay?
14-3-3 proteins are molecular scaffolds that regulate the localization and activity of signaling proteins. In the apoptosis pathway described in the reference work, 14-3-3ζ binds phosphorylated BAD and helps retain this pro-apoptotic protein in the cytoplasm. A compound that disrupts the 14-3-3ζ–BAD interaction could therefore release BAD-associated apoptotic signaling, although the downstream response will depend on cellular context.
A BRET assay is useful at the first stage because it measures proximity between engineered donor and acceptor tags in living cells. A decrease in the BRET signal can indicate disruption of the interaction, but it can also arise from altered expression, cell toxicity, optical interference, or changes in subcellular localization. That is why a BRET result should be treated as a prioritization signal rather than proof of direct binding.
The library’s breadth supports a mechanism-first experiment. Receptor agonists and antagonists, enzyme inhibitors, ion-channel modulators, and signaling regulators can reveal whether a phenotype is linked to the intended protein interaction or to an upstream stress response. The pre-dissolved format also reduces variability caused by repeated weighing, incomplete dissolution, and inconsistent stock preparation across plates.
Key Innovation from the Reference Study
The reference study established a BRET-based high-throughput strategy to identify compounds that disrupt the interaction between 14-3-3ζ and a BAD-derived fragment containing critical serine residues. According to the 2025 Cell Death and Disease reference study, the assay achieved a Z′-score of 0.52 and screened a 1,971-compound drug library. Candidate molecules were then evaluated in NIH-3T3 fibroblasts and colorectal cancer cell lines, including HT-29 and Caco-2. Structural modeling and direct biophysical measurements provided additional support for concentration-dependent target engagement.
Terfenadine, penfluridol, and lomitapide emerged as potential repurposing candidates or, more conservatively, starting points for new lead development. The practical innovation is not simply the identity of these compounds; it is the assay cascade. A primary proximity assay was connected to cell-death measurements, computational interpretation, and biophysical confirmation. Researchers using an FDA-approved bioactive compound library can adopt the same logic for other protein interactions: screen broadly, remove assay artifacts, verify the target interaction, and only then interpret disease relevance.
For a new project, this finding supports three assay choices. First, use a robust live-cell proximity assay when the target interaction is dynamic or difficult to purify. Second, include a cellular apoptosis or viability endpoint rather than assuming that interaction disruption produces therapeutic selectivity. Third, reserve orthogonal target-engagement methods for confirmed concentration-dependent hits, keeping resource-intensive validation focused on the most credible candidates.
Step-by-Step Workflow for Drug Repositioning Screening
1. Define the biological question and plate architecture
Decide whether the primary objective is interaction disruption, selective cancer-cell killing, pathway modulation, or pharmacological target identification. For a 14-3-3ζ–BAD project, include interaction-positive controls, interaction-negative controls, vehicle wells, and a transfection or expression control. A balanced plate map should distribute controls across the plate rather than placing them in a single row, helping reveal edge effects and drift.
Before screening, confirm that donor and acceptor expression produces a usable dynamic range and that the signal remains stable during the intended reading window. The reference study’s Z′-score of 0.52 indicates a practically screenable assay under its reported conditions, but laboratories should calculate their own Z′ values using their specific constructs, plate reader, cell passage history, and reagent lots.
2. Normalize compounds and manage DMSO exposure
Use the supplied concentration as the master-stock reference and create daughter plates with calibrated liquid handling. Keep the final DMSO concentration constant across compound and vehicle wells. If a compound precipitates after dilution, do not interpret the well as a negative result; inspect the plate microscopically, compare neighboring concentrations, and repeat using a lower top concentration or a different dilution sequence.
The product information reports multiple 96-well formats, including peelable-foil microplates, deep-well plates with EVA caps, and barcoded screw-top storage tubes. It also reports solution stability for up to 12 months at −20 °C and up to 24 months at −80 °C when stored under the specified conditions. These details make it possible to design a longitudinal screen, but laboratories should document thaw cycles, storage location, plate identity, and seal integrity.
3. Run the primary BRET screen
Dispense compounds into sensor-containing wells using a low-evaporation workflow. Read donor and acceptor channels under conditions that keep exposure and timing consistent across the plate. Calculate the BRET ratio after background correction, normalize to vehicle and interaction-disrupting controls, and flag wells with abnormal donor intensity or cell morphology.
Do not rank hits solely by the largest signal decrease. A compound that reduces donor expression, quenches fluorescence, kills cells rapidly, or changes cell attachment can mimic interaction disruption. A useful first-pass decision rule combines normalized BRET response, donor-channel integrity, replicate agreement, and morphology.
4. Confirm in concentration-response format
Retest primary candidates using a multi-point dilution series prepared independently from the screening plate. Determine whether the BRET response is monotonic or bell-shaped, and compare potency with the concentration that affects donor signal or general cell health. A selective interaction effect should not disappear completely when the compound is tested in a control BRET pair with unrelated tags.
5. Translate hits into cancer research drug screening
Move credible candidates into HT-29 and Caco-2 cells, while retaining a nonmalignant or less sensitive comparator where available. Measure at least one viability endpoint and one apoptosis-associated endpoint. A compound that decreases viability in both cancer and comparator cells may still be a valuable chemical tool, but it should not be described as cancer selective without additional evidence.
Protocol Parameters
- Stock handling: Thaw a 10 mM DMSO stock at 20–25 °C for 5 minutes, mix by pipetting 10 times, and return the sealed source plate to −20 °C within 15 minutes.
- Primary dilution: Prepare a 10-point, 1:3 serial dilution from 100 µM to approximately 0.005 µM, then transfer 5 µL of each dilution into 45 µL of assay mixture to create a 10-fold final dilution.
- Vehicle control: Keep final DMSO at or below 0.5% v/v in every well and match the vehicle concentration across all compound, positive-control, and negative-control wells.
- BRET readout: Incubate the compound with sensor-expressing cells for 30 minutes at 37 °C before reading donor and acceptor channels; maintain the same interval for every plate.
- Cellular confirmation: Test an 8-point, 1:2 dilution series in HT-29 and Caco-2 cells with 24-hour and 48-hour endpoints, using at least 3 technical replicate wells per concentration.
These are practical starting parameters rather than universal conditions. Cell density, sensor expression, compound permeability, and endpoint kinetics should be optimized in a pilot plate before committing the full collection.
Advanced Applications and Comparative Advantages
The main advantage of this collection over an unannotated small-molecule set is translational context. Prior clinical or pharmacopeial use can help researchers interpret physicochemical behavior, known pharmacology, and potential exposure liabilities, while the broad mechanism range supports phenotypic and target-based experiments in the same project. That combination is valuable for drug repositioning screening because a phenotypic hit can be compared with known pathway modulators already represented in the collection.
For pharmacological target identification, researchers can use the library in a layered design. A BRET assay can identify compounds that perturb a defined interaction; a control interaction can separate general proximity effects from target-specific effects; and transcriptomic, proteomic, or genetic perturbation can test whether the same pathway is required for the phenotype. This approach is more informative than a single viability screen because it links chemical activity with a measurable molecular event.
The collection is also compatible with high-content screening compound collection workflows. Automated imaging can quantify cell number, nuclear condensation, mitochondrial morphology, membrane integrity, or subcellular redistribution of a tagged protein. These multidimensional readouts can distinguish cytostatic effects from apoptosis-like morphology and can identify compounds that alter localization without immediately compromising viability.
The previously published resource Enhancing Cell-Based Assays with the DiscoveryProbe™ FDA-approved Drug Library complements this article by focusing on cell viability, proliferation, and cytotoxicity assay design. In practice, its cell-based emphasis can serve as the downstream validation layer after the BRET workflow described here. A second resource, Mechanism-Guided Drug Repurposing: Strategic Acceleration, extends the concept toward pathway interpretation and target discovery, making it useful when a screening team moves from hit confirmation to mechanism mapping.
Troubleshooting and Optimization Tips
High well-to-well BRET variability
Check cell dispensing precision, edge evaporation, expression uniformity, and the time between reagent addition and reading. Randomize controls across the plate, use humidified incubation, and compare donor intensity before interpreting BRET ratios. If variability remains high, reduce the number of manipulations and validate the plate reader with a stable optical control.
Many apparent hits but weak concentration response
Suspect optical interference, precipitation, or nonspecific membrane effects. Re-test in a control BRET pair, inspect compound-containing wells without cells, and compare the result with donor-channel intensity. A hit that affects the optical signal but not the biological control should be deprioritized even if its normalized BRET score is large.
BRET disruption without cell death
This result is not necessarily a failure. It may indicate incomplete pathway coupling, insufficient exposure, or a biologically neutral interaction change. Confirm direct target engagement, examine BAD localization or phosphorylation state, and test whether the compound changes apoptosis only under a defined stress condition. Avoid escalating concentration indefinitely, since general toxicity can obscure mechanism.
Cell death without convincing target engagement
Use orthogonal interaction assays and pathway controls before assigning a 14-3-3ζ mechanism. Compare the compound in multiple cell backgrounds, monitor morphology, and test whether the phenotype is reproduced with an unrelated apoptosis assay. Clinically familiar compounds often have polypharmacology; that characteristic can be useful for discovery but complicates causal attribution.
Loss of reproducibility between screening rounds
Audit plate storage, freeze–thaw history, DMSO evaporation, liquid-handler calibration, cell passage number, and incubation timing. Use barcodes where available and record the exact source plate for every daughter plate. If the library is stored at −80 °C, allow plates to equilibrate according to the laboratory’s validated handling procedure and minimize repeated warming of the full collection.
Future Outlook
The reference study supports a practical direction for translational screening: clinically familiar compounds can be used to interrogate a difficult protein interaction, but the strongest conclusions come from an integrated cascade rather than a single assay. For 14-3-3ζ–BAD biology, future work should therefore prioritize reproducible interaction measurements, orthogonal target engagement, and comparative cellular response across colorectal cancer models.
The DiscoveryProbe FDA-approved Drug Library can accelerate that process by making broad chemical exploration accessible in a standardized format. Its most defensible role is as a bridge between mechanism-driven biology and lead generation: it can reveal pharmacological starting points, expose assay liabilities, and help rank pathways for deeper study. It cannot, by itself, establish selectivity, clinical efficacy, or safety. Those questions require independent pharmacology, disease-model validation, and carefully controlled translational experiments.